About Moberg Pharma

Dr. Sven Moberg worked at Sahlgrenska University Hospital since the 1980s and devoted his career to the development and improvement of dermatological treatments for common but challenging diseases such as nail fungus. Dr. Moberg's work serves as the foundation for Moberg Pharma. The company was established in 2006 at Karolinska Institutet, based on Dr. Moberg's research.

Moberg Pharma’s goal is to make MOB-015 the world’s leading treatment for nail fungus and to build a specialty pharmaceutical company with its own sales in the U.S. and sales through partners in other markets. With MOB-015 as an anchor, the company intends to expand the product portfolio with additional products in adjacent areas either developed in-house or acquired. MOB-015 is currently approved in 13 European countries. MOB-015 is launched in Sweden since spring 2024, under the brand name Terclara®. The product is a market leader in Sweden, and the launch has won the "Launch of the Year" award from the pharmacy chains Kronans Apotek and DOZ Apotek. The Swedish launch, where Terclara® captured a 39% market share while growing the nail fungus category as a whole by 46%, demonstrates the potential for larger markets and how quickly a market-leading position can be achieved with a strong product profile.

The company intends to repeat the journey that was made with Kerasal Nail®, the company’s first-generation nail fungus product, combining direct sales in the U.S. with strategic collaborations in a number of major regions. The most important markets for MOB-015 are expected to be the U.S., EU, Japan, Canada and China, all with approved patent protection through 2032. In addition to granted patents, the company also has ongoing patent applications which, if approved, could provide significantly longer patent protection.

The results from clinical Phase 3 studies with 800+ patients indicate that MOB-015 has the potential to become the future market leader in the treatment of nail fungus. MOB-015 is developed based on Moberg Pharma’s patented formulation technology, which facilitates the delivery of high concentrations of the proven antifungal substance terbinafine through the nail.

A total of five agreements with commercial partners are in place for MOB-015: Cipher Pharmaceuticals for Canada; Allderma in Scandinavia and Padagis in Israel. The agreements give these partners exclusive rights to market and sell MOB-015 in their respective markets, while Moberg Pharma has production and supply responsibility.